Search results
Results from the WOW.Com Content Network
It is indicated in the treatment of schizophrenia and schizoaffective disorder. [14] It is marketed by Janssen Pharmaceuticals. [4] Paliperidone was approved by the US Food and Drug Administration (FDA) for the treatment of schizophrenia in December 2006, [4] and in the European Union in June 2007. [8]
A new first-in-class antipsychotic that targets multiple neurotransmitter systems called lumateperone (ITI-007), was trialed and approved by the FDA in December 2019 for the treatment of schizophrenia in adults. [24] [26] [27] Lumateperone is a small molecule agent that shows improved safety, and tolerance.
Though not approved for treatment use by the FDA, research suggests that Clozapine may also be effective in treating schizoaffective disorder, particularly in those resistant to initial medication. [82] Clozapine is an atypical antipsychotic that is recognized as being particularly effective when other antipsychotic agents have failed. [83]
The U.S. Food and Drug Administration (FDA) on Friday approved a new drug used for treating schizophrenia in adults, according to a press release. “This drug takes the first new approach to ...
Clozapine, sold under the brand name Clozaril among others, is a psychiatric medication and was the first atypical antipsychotic to be discovered. [6] It is primarily used to treat people with schizophrenia and schizoaffective disorder who have had an inadequate response to two other antipsychotics, or who have been unable to tolerate other drugs due to extrapyramidal side effects.
Lithium Lithium is the "classic" mood stabilizer, the first to be approved by the US FDA, and still popular in treatment. Therapeutic drug monitoring is required to ensure lithium levels remain in the therapeutic range: 0.6 to 0.8 or 0.8–1.2 mEq/L (or millimolar).
A new opioid-free pain medication was approved by the U.S. Food and Drug Administration (FDA) on Thursday, marking a non-addictive alternative for patients. Journavx (suzetrigine), made by Vertex ...
The U.S. Food and Drug Administration (FDA) approved Journavx (suzetrigine) oral tablets on Thursday as a first-in-class non-opioid analgesic to treat acute pain in adults.